Abstract:BACKGROUND: Autoimmune liver disease (AILD) has been considered a relatively uncommon disease in China, epidemiological data for AILD in patients with cirrhosis and acute decompensation (AD) is sparse.AIM: To investigate the prevalence, outcome and risk factors for AILD in cirrhotic patients complicated with AD in China.METHODS: We collected data from patients with cirrhosis and AD from two prospective, multicenter cohorts in hepatitis B virus endemic areas. Patients were regularly followed up at the end of 28-d, 90-d and 365-d, or until death or liver transplantation (LT). The primary outcome in this study was 90-d LT-free mortality. Acute-on-chronic liver failure (ACLF) was assessed on admission and during 28-d hospitalization, according to the diagnostic criteria of the European Association for the Study of the Liver (EASL). Risk factors for death were analyzed with logistic regression model.RESULTS: In patients with cirrhosis and AD, the overall prevalence of AILD was 9.3% (242/2597). Prevalence of ACLF was significantly lower in AILD cases (14%) than those with all etiology groups with cirrhosis and AD (22.8%) (<i>P</i> < 0.001). Among 242 enrolled AILD patients, the prevalence rates of primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) and PBC-AIH overlap syndrome (PBC/AIH) were 50.8%, 28.5% and 12.0%, respectively. In ACLF patients, the proportions of PBC, AIH and PBC/AIH were 41.2%, 29.4% and 20.6%. 28-d and 90-d mortality were 43.8% and 80.0% in AILD-related ACLF. The etiology of AILD had no significant impact on 28-d, 90-d or 365-d LT-free mortality in patients with cirrhosis and AD in both univariate and multivariate analysis. Total bilirubin (TB), hepatic encephalopathy (HE) and blood urea nitrogen (BUN) were independent risk factors for 90-d LT-free mortality in multivariate analysis. The development of ACLF during hospitalization only independently correlated to TB and international normalized ratio.CONCLUSION: AILD was not rare in hospitalized patients with cirrhosis and AD in China, among which PBC was the most common etiology. 90-d LT-free mortality were independently associated with TB, HE and BUN.

Autoimmune Liver Injury and Non-alcoholic Fatty Liver Disease

ASSA13-10-11 Nonalcoholic Fatty Liver Disease is Associated with Subclinical Atherosclerosis

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Study on the Relationship between Phospholipids and Nonalcoholic Fatty Liver Disease

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

Clinical Analysis of 187 Patients with Autoimmune Liver Diseases

Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China

Autoantibodies profile in autoimmune liver diseases and chronic viral hepatitis

Non-alcoholic Fatty Liver Disease and Hepatic Lipotoxicity

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

Analysis of Prognosis and Coexistence with Other Autoimmune Diseases in 232 Patients with Autoimmune Liver Disease

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

The interplay between non-alcoholic fatty liver disease and innate immunity in hepatitis B virus patients

Detection of Autoantibodies in Chronic Liver Disease and Its Correlation with Autoimmune Liver Diseases

Innate immunity and nonalcoholic fatty liver disease

Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Innate Immune Response in Non Alcoholic Fatty Liver Disease: An Overview of Alterations in TLR9, Macrophages, and TNFα